255 related articles for article (PubMed ID: 30536154)
1. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
Shaik N; Hee B; Wei H; LaBadie RR
Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers.
Giri N; Lam LH; LaBadie RR; Krzyzaniak JF; Jiang H; Hee B; Liang Y; Shaik MN
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1249-1260. PubMed ID: 29086063
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
Shaik MN; Hee B; Wei H; LaBadie RR
Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303
[TBL] [Abstract][Full Text] [Related]
4. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
[TBL] [Abstract][Full Text] [Related]
5. Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.
Shaik N; Hee B; Liang Y; LaBadie RR
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):895-902. PubMed ID: 30977980
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study.
Masters JC; LaBadie RR; Salageanu J; Li J; Shaik N
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):707-717. PubMed ID: 33356019
[TBL] [Abstract][Full Text] [Related]
8. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Bioequivalence, and Safety Studies of Pantoprazole Sodium Enteric-Coated Tablets in Healthy Subjects.
Chen Z; Gan F; Rao X; Huang X; Chen H
Clin Pharmacol Drug Dev; 2021 May; 10(5):502-509. PubMed ID: 33128847
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of rabeprazole granules versus tablets, and the effect of food on the pharmacokinetics of rabeprazole granules in healthy adults-cross-study comparison.
Thyssen A; Solanki B; Gonzalez M; Leitz G; Treem W; Mannaert E
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):406-16. PubMed ID: 27129014
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Safety of Posaconazole Administered by Intravenous Solution and Oral Tablet in Healthy Chinese Subjects and Effect of Food on Tablet Bioavailability.
Li H; Wei Y; Zhang S; Xu L; Jiang J; Qiu Y; Mangin E; Zhao XM; Xie S
Clin Drug Investig; 2019 Nov; 39(11):1109-1116. PubMed ID: 31432392
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
Shaik MN; LaBadie RR; Rudin D; Levin WJ
Cancer Chemother Pharmacol; 2014 Aug; 74(2):411-8. PubMed ID: 24944041
[TBL] [Abstract][Full Text] [Related]
13. Bioequivalence of a Newly Developed Dabigatran Etexilate Tablet Versus the Commercial Capsule and Impact of Rabeprazole-Induced Elevated Gastric pH on Exposure in Healthy Subjects.
Harada A; Ikushima I; Haranaka M; Yanagihara A; Nakayama D
Am J Cardiovasc Drugs; 2020 Jun; 20(3):249-258. PubMed ID: 31667735
[TBL] [Abstract][Full Text] [Related]
14. Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials.
Devarakonda K; Kostenbader K; Giuliani MJ; Young JL
BMC Pharmacol Toxicol; 2015 Nov; 16():31. PubMed ID: 26614499
[TBL] [Abstract][Full Text] [Related]
15. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption.
Moore KH; Shaw S; Laurent AL; Lloyd P; Duncan B; Morris DM; O'Mara MJ; Pakes GE
J Clin Pharmacol; 1999 Jun; 39(6):593-605. PubMed ID: 10354963
[TBL] [Abstract][Full Text] [Related]
16. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability and Pharmacokinetics of TRPV1 Antagonist Mavatrep (JNJ-39439335) Tablet and Capsule Formulations in Healthy Men: Two Open-Label, Crossover, Single-Dose Phase 1 Studies.
Manitpisitkul P; Shalayda K; Russell L; Sanga P; Williams Y; Solanki B; Caruso J; Moyer JA
Clin Pharmacol Drug Dev; 2018 Sep; 7(7):699-711. PubMed ID: 29125700
[TBL] [Abstract][Full Text] [Related]
18. Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BIĀ 853520.
Verheijen RB; van der Biessen DAJ; Hotte SJ; Siu LL; Spreafico A; de Jonge MJA; Pronk LC; De Vos FYFL; Schnell D; Hirte HW; Steeghs N; Lolkema MP
Target Oncol; 2019 Feb; 14(1):67-74. PubMed ID: 30742245
[TBL] [Abstract][Full Text] [Related]
19. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
20. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]